Search for a trial

Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts

Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):- Determine the MTD with and/or determine the RP2D of GEN3009- Evaluate safety and tolerability of GEN3009Expansion (GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):-Evaluate (preliminary)…

Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study.

This study has been transitioned to CTIS with ID 2024-518422-32-01 check the CTIS register for the current data. Primary objectives: The first primary objective is to study the expression of PD-L1 in normal tissue and lymphoma lesions before CAR T-…

A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies

Primary:- To determine the safety, tolerability, and dose-limiting toxicities (DLTs) of MCLA-145 and to determine an MTD and/or the RDE in advanced or metastatic solid tumors or B-cell lymphomas.Secondary:- To explore preliminary antitumor activity…

A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

to determine the safety and efficacy of CTL019 in adults with relapsed or refractory DLBCL and to monitor all patients exposed to CTL019 for 5 years following CTL019 infusion

A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Primary: • Part 1:To evaluate the efficacy of NIR178 and PDR001 combination in patients with selected advanced solid tumors and diffuse large B cell lymphoma (DLBCL). • Part 2: To assess the efficacy of several intermittent dosing schedules of…

Primary Cerebral Lymphoma at UMCU and St Antonius

Conducting research into the role of CSF and blood parameters of patients with CNS lymphoma, focused on improving the diagnostics, identification of biomarkers ('liquid biopsy'), and evaluation of therapy effect.

A phase 2 immunoPET imaging study with ZED88082A/CED88004S in patients with Large B-cell lymphoma before and after CD19-directed CAR T-cell therapy

Primary objectives:The objective is to study the distribution of CD8+ T-cells before and after CAR T-cell therapy in the patient by ZED88082A/CED88004S-PET imaging. We will correlate the pretreatment CD8+ T-cell distribution and CD8+ CAR T-cell…

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

This study has been transitioned to CTIS with ID 2022-502661-23-00 check the CTIS register for the current data. The primary objective of the study is to evaluate the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects…

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

This study has been transitioned to CTIS with ID 2024-511616-24-00 check the CTIS register for the current data. Primary ObjectivesPhase 1a:• Evaluate the safety of KITE-363 in subjects with r/r B-cell lymphoma• Determine the dose level(s) for Phase…

Phase 1b/2, Open Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-505347-38-00 check the CTIS register for the current data. The primary objectives of the study are to characterize the safety and toxicity profiles of epcoritamab when co-administered with anti-…

Testing of a new antibody therapy using blood from children with B-cell Non-Hodgkin lymphoma.

Within the immunotherapy group, a new panel of anti-CD20 monoclonals have been generated that are currently produced as chimeric IgG and IgA formats. We intend to demonstrate the efficacy and the anticipated superiority of IgA versus IgG and…

An Open-label, Phase 2 Study of ACP-196 in Subjects
with Waldenström Macroglobulinemia

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of ACP-196 in treating subjects with Waldenström disease.

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton*s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

This study has been transitioned to CTIS with ID 2023-510541-25-00 check the CTIS register for the current data. This study*s phase 1a primary objectives are:• To evaluate the safety and tolerability of BTK degrader NX-5948, when taken orally, in…

An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy, activity, safety, pharmacodynamics and pharmacokinetics of ACP-196 in treating subjects with Mantle Cell Lymphoma (MCL)

MUSCLE study - Mitochondrial dysfUnction: a key player in doxorubicin-induced Skeletal and Cardiac muscLE damage?

To demonstrate the ability of using non-invasive 31P-MRS to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles (i.e., skeletal muscle PCr recovery rate constant and cardiac PCr/ATP ratio) in DLBCL patients…

Response assessment of post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility study

1 - To determine the feasibility of MRD detection using next generation sequencing (NGS) on circulating tumor DNA (ctDNA) from PTLD patients using a gene panel previously used in diffuse large B-cell lymphoma (DLBCL) 2 - To explore the mutational…

Molecular imaging of zirconium-89-labeled atezolizumab as a tool to investigate atezolizumab biodistribution in diffuse large B-cell lymphoma

Primary objective:• To evaluate biodistribution of 89Zr-atezolizumab in patients with high risk DLBCL at diagnosis.Secondary objective:• To assess the heterogeneity of 89Zr-atezolizumab tumor uptake in high-risk DLBCL before R-CHOP.• To correlate…

A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents

Primary: To assess best overall response rate (ORR) up to 8 cycles. Secondary: ORR, complete response (CR), very good partial response (VGPR), progression free survival (PFS), overall survival (OS), safety, PK, exposure-response (efficacy and safety…

ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients >= 18 years with relapsed follicular lymphoma
A HOVON/GLSG/ NCRI study

The objective of the study is to investigate the feasibility and efficacy of treatment with lenalidomide and rituximab with or without bendamustine in patients with relapsed follicular lymphoma.

A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA)

Primary: To evaluate the efficacy of tisagenlecleucel therapy as measured by overall response rate by investigator assessment.Secondary: Duration of response, event free survival, relapse free survival, overall survival, safety, kinetics,…